Neumann, Olaf http://orcid.org/0000-0003-2684-9187
Burn, Timothy C.
Allgäuer, Michael
Ball, Markus
Kirchner, Martina
Albrecht, Thomas
Volckmar, Anna-Lena
Beck, Susanne
Endris, Volker
Goldschmid, Hannah
Lehmann, Ulrich http://orcid.org/0000-0003-2350-6584
Seker-Cin, Huriye
Uhrig, Sebastian
Roessler, Stephanie http://orcid.org/0000-0002-5333-5942
Budczies, Jan http://orcid.org/0000-0002-6668-5327
Fröhling, Stefan
Longerich, Thomas http://orcid.org/0000-0001-8888-1030
Wagner, Alex H.
Vogel, Arndt http://orcid.org/0000-0003-0560-5538
Schirmacher, Peter
Stenzinger, Albrecht
Kazdal, Daniel http://orcid.org/0000-0001-8187-3281
Funding for this research was provided by:
German Cancer Consortium (DKTK), Heidelberg, Germany
Article History
Received: 7 February 2022
Revised: 23 June 2022
Accepted: 29 June 2022
First Online: 23 July 2022
Ethics approval and consent to participate
: None.
: None.
: ON reports personal fees from Novartis outside the submitted work. TB formerly employed by Incyte. AV reports personal fees from AstraZeneca outside the submitted work. JB reports a grand from the German Cancer Aid outside the submitted work. SF Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche. TL reports a personal fee from Incyte outside the submitted work. PS reports personal fees from BMS, MSD, Incyte, Janssen, Amgen, Novartis, Roche and AstraZeneca outside the submitted work. AS reports grants and personal fees from Bayer, BMS, grants from Chugai and personal fees from AstraZeneca, MSD, Takeda, Seattle Genetics, Novartis, Illumina, Thermo Fisher, Eli Lily, Takeda, outside the submitted work. DK reports personal fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, Lilly, Agilent and Takeda outside the submitted work. The remaining authors declare no competing interests.